GDT002 / Century Therap - LARVOL DELTA

A patient-derived organoid platform to assess the effectiveness of γδTCR cell therapy in solid tumors (AACR 2024) - "Interestingly, GDT002 was particularly efficient at killing ovarian cancer-derived PDOs, allowing Gadeta to move GDT002 to clinical trials for this indication confidently. This study reveals that our tumor organoid co-culture with engineered T cells platform holds significant value for the preclinical development of cellular therapies."

Clinical • Colorectal Cancer • Hematological Malignancies • Oncology • Ovarian Cancer • Solid Tumor

Targeting ovarian carcinoma with GDT002, a first-in-class γδTCR-based T cell therapy (SITC 2022) - P1 | "Tumor reactivity was tested in 2D co-cultures in the presence or absence of pamidronate, a clinically approved aminobisphosphonate that boosts pAgs levels. Conclusions We demonstrate that GDT002 has potent anti-tumor activity across a broad spectrum of solid tumors. Based on the unmet clinical need and preclinical studies, recurrent ovarian cancer was selected as the first solid tumor indication to evaluate the efficacy of GDT002."

Hematological Malignancies • Multiple Myeloma • Oncology • Ovarian Cancer • Solid Tumor • BTN3A1 • BTN3A2

Targeting solid tumors with GDT002, a first-in-class γδTCR-based T cell therapy (AACR 2022) - P1 | "Tumor reactivity was tested against cell lines from different cancer types in the presence of pamidronate, a clinically approved N-bisphosphonate that boosts pAgs levels. Taken together, our results demonstrate that GDT002 has a potent anti-tumor activity across a broad spectrum of solid and liquid tumor types. We have identified ovarian cancer as a potential indication to explore the clinical effect of GDT002 against solid tumors."

Hematological Malignancies • Multiple Myeloma • Oncology • Ovarian Cancer • Solid Tumor

Gadeta Appoints Scientific Advisory Board and Provides Business Update (PRNewswire) - "Gadeta expects to progress two solid tumor cell therapy programs towards the clinic in 2023. Its first program, GDT002, is based on a γ9δ2 TCR that targets a protein broadly expressed in both hematological as well as solid tumors.... Gadeta will now focus the clinical development of GDT002 in solid tumors and already has an open IND. The second program, GDT201, comprises a non-δ2 TCR targeting a surface protein shown to be modified in a variety of solid tumors....GDT201 will be evaluated in a phase I trial for select solid tumor indications, slated to start in H2 2023....Gadeta continues to scale up its NOVA γδ TCR discovery platform to expand its portfolio of proprietary tumor specific γδ TCRs....Gadeta will also broaden the application of γδ TCRs with other biological formats to leverage the unique tumor targeting properties of γδ TCRs."

New P1 trial • Pipeline update • Hematological Malignancies • Oncology • Solid Tumor

A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients (clinicaltrials.gov) - P1 | N=26 | Active, not recruiting | Sponsor: Gadeta B.V. | Recruiting ➔ Active, not recruiting

Enrollment closed • Hematological Malignancies • Multiple Myeloma • Oncology • IL6

Gadeta to Present Data on Tumor-Specific Cell Therapies at Leading Scientific Conferences (PRNewswire) - "Gadeta B.V....announce that Chief Executive Officer Marcel Zwaal and Chief Scientific Officer Mark Throsby will be presenting data on γδ TCR-based immunotherapies for solid tumors at the following upcoming scientific conferences"

Clinical data • Oncology • Solid Tumor

[VIRTUAL] αβ-T cells engineered to express γδ-T cell receptors can kill neuroblastoma organoids independent of MHC-I expression (ITOC 2021) - "Conclusions We demonstrated that 50% of tested neuroblastoma organoids can effectively activate TEG002 and that killing of the organoids is independent of MHC-I expression. Hence, this pilot study identified TEG002 as a promising novel cellular product for immunotherapy for a subset of neuroblastoma tumors, warranting further investigations into its clinical application."

IO biomarker • Neuroblastoma • Oncology • Solid Tumor • CASP3 • CASP7 • IFNG

αβ-T Cells Engineered to Express γδ-T Cell Receptors Can Kill Neuroblastoma Organoids Independent of MHC-I Expression. (PubMed, J Pers Med) - "Of note, efficacy of TEG002 treatment was superior to donor-matched untransduced αβ-T cells or endogenous γδ-T cells. Our data suggest that TEG002 may be a promising novel treatment option for a subset of neuroblastoma patients."

IO biomarker • Journal • Neuroblastoma • Oncology • Solid Tumor • IFNG

A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients (clinicaltrials.gov) - P1; N=26; Recruiting; Sponsor: Gadeta B.V.; Initiation date: Feb 2021 ➔ May 2021

Clinical • Trial initiation date • Hematological Malignancies • Multiple Myeloma • Oncology • IL6

First Patient Dosed with Gadeta’s gamma delta TCR Cell Therapy (PRNewswire) - “Gadeta…announced the dosing of the first patient with GDT-002 (formerly labelled TEG002), a potential first-in-class cellular immunotherapy for the treatment of cancer.The multicenter phase 1/2 study in collaboration with the Dana-Farber Cancer Institute, Mass General Brigham Cancer Care and Beth Israel Deaconess Medical Center, is evaluating safety, tolerability and preliminary efficacy of GDT-002 for the treatment of multiple myeloma (MM)…The target recognized by GDT-002 is upregulated in a wide range of liquid and solid tumors, presenting great therapeutic potential.”

Trial status • Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor